Last reviewed · How we verify
Intraosseous Morphine
At a glance
| Generic name | Intraosseous Morphine |
|---|---|
| Also known as | Duramorph, Astramorph PF, Infumorph |
| Sponsor | The Methodist Hospital Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty (PHASE2)
- Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous and Peri-articular Injection (PHASE4)
- Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction (PHASE4)
- Intraosseous Morphine in Primary TKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraosseous Morphine CI brief — competitive landscape report
- Intraosseous Morphine updates RSS · CI watch RSS
- The Methodist Hospital Research Institute portfolio CI